Baxter shares dented by HemAssist data demand
This article was originally published in Clinica
Executive Summary
Despite the strong dollar, Baxter's sales rose 14% in both the third quarter and the first nine months, to $1,494 million and $4,506 million. However, last week its share price was hit by news that the European drug regulatory agency has asked for further clinical data on its blood substitute, HemAssist.